September 13, 2022
Life Sciences
  • An analysis conducted by the Community Oncology Alliance (COA) found that safety net hospitals are marking up the cost of drugs they buy through the federal 340B drug program by as much as 11 times the cost. The COA examined self-reported drug pricing data for 49 of the top acute care hospitals in 340B that see a disproportionate share of poor patients. Based on the assumption that acute care hospitals were receiving a 34.7 percent discount on the average sales price of the drugs, the median markup of the oncology drugs studied was 4.9 times hospitals’ acquisition costs. (Report here)